glp-1 receptor agonists effects on cardiovascular risk reduction Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction The Role of GLP-1RA Medications

Metabolic endotoxemia initiates obesity and insulin resistance

Each additional compound introduces its own side effect profile, interaction potential, and pharmacokinetic considerations

In a phase II trial, participants with obesity were randomly assigned to various doses of retatrutide from 14 , 8, or 12 mg or a placebo for 48 weeks [19]

Acknowledgments This project was initiated by the Obesity Management Collaboration-UK (OMC-UK), which is a professional support network of healthcare professionals with an interest in obesity treatment

Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway

In conclusion, both SGLT2-i and GLP1-RA seem to have several effects on RAAS, though additional studies are needed to clarify this relationship